New pill shows promise for Hard-to-Treat cancers in early trial
NCT ID NCT06568614
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new oral drug called BG-89894 (SYH2039) in 29 adults with advanced solid tumors that have a specific genetic deletion (MTAP). The main goals were to check safety, find the right dose, and see if the drug shows any signs of shrinking tumors. The trial was terminated, so final results may be limited.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- BG-89894 (SYH2039) tablet
- What this could lead to
- If this drug proves safe and shows early signs of shrinking tumors, it could lead to a new treatment option for people with advanced solid tumors that have a specific genetic change (MTAP deletion).
- What could go wrong
- This is a very early (Phase 1) study with only 29 participants, so the drug may not work or may cause serious side effects. The trial was terminated, meaning results may be incomplete.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
29 people
The number who actually took part.
- Started
-
Oct 2024
- Finished
-
Apr 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Key Inclusion Criteria: * Must sign a written informed consent and willing to comply with all study-related procedures and requirements. * Age ≥18 years (or the legal age of consent according to local regulations). * Histologically or cytologically confirmed diagnosis of advanced, metastatic, or unresectable solid tumors that have progressed on or after standard therapy, or for which no appropriate standard therapy is available. * Evidence of Methylthioadenosine phosphorylase (MTAP) homozygous deletion or loss of MTAP expression in tumor tissue. * Participants must be able to provide an archived tumor tissue sample or unstained fresh biopsy if there is no archival tissue at baseline. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and evidence of adequate organ function and bone marrow reserve, as defined in the study protocol. Key Exclusion Criteria: * History of other malignancies or concurrent active malignancies within 3 years. * Prior treatment with methionine adenosyltransferase 2 alpha (MAT2A) inhibitors (e.g., AG-270, IDE397) or methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors (e.g., AMG193). * Uncontrolled or active central nervous system (CNS) disease, including untreated or symptomatic brain metastases, spinal cord compression, or leptomeningeal carcinomatosis. * Active bleeding, history of major bleeding events within the past 6 months, or tumors associated with a high risk of vascular invasion. * Receipt of systemic anticancer therapy, radiation therapy, live vaccine, or major surgical procedures within protocol-specified washout periods. * Active or uncontrolled infections, including tuberculosis (TB), (COVID-19, known human immunodeficiency virus (HIV) infection, or uncontrolled hepatitis B virus (HBV) infection. Note: Additional eligibility criteria may apply.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Advanced or metastatic MTAP-deleted solid tumors are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Beijing Tsinghua Changgung Hospital
Beijing, Beijing Municipality, 102218, China
-
Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, NSW 2148, Australia
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
-
Cancer Research South Australia
Adelaide, South Australia, SA 5000, Australia
-
Columbia University Irving Medical Center
New York, New York, 10032-3725, United States
-
Guangdong Provincial Peoples Hospital Huifu Branch
Guangzhou, Guangdong, 510120, China
-
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, 530021, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
-
Linear Clinical Research
Nedlands, Western Australia, WA 6009, Australia
-
Next Virginia
Fairfax, Virginia, 22031, United States
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200433, China
-
Sidney Kimmel Comprehensive Cancer At Johns Hopkins
Baltimore, Maryland, 21287, United States
-
St Vincents Hospital
Fitzroy, Victoria, VIC 3065, Australia
-
The First Hospital of China Medical University Hunnan Branch
Shenyang, Liaoning, 110167, China
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050011, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
-
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
-
Washington University School of Medicine
St Louis, Missouri, 63110-1010, United States
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China